EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma

Tsung-I Hsu iD, Yi-Ping Chen iD, Rong-Lin Zhang, Zih-An Chen, Cheng-Hsun Wu, Wen-Chang Chang, Chung-Yuan Mou iD, Hardy Wai-Hong Chan, Si-Han Wu iD

ACS Applied Materials & Interfaces · 2024

DOI: 10.1021/acsami.4c04289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Tsung-I Hsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, …. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Docetaxel, Silicon Dioxide. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, TMU Industry-Academic Cooperation Program, ScinoPharm Taiwan, Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaDocetaxelSilicon DioxideBlood-Brain BarrierNanoparticlesDrug Resistance, NeoplasmAnimalsHumansMiceBrain NeoplasmsCell Line, TumorPorosityDrug CarriersMice, NudeAntineoplastic AgentsApoptosis

Stichwörter der Autor:innen

blood−brain tumor barrierdocetaxelglioblastomamesoporous silica nanoparticlestemozolomide resistant

Substanzen

TemozolomideDocetaxelSilicon DioxideDrug CarriersAntineoplastic Agents

Autor:innen und Institutionen

  • Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan.
  • International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
  • Graduate Institute of Nanomedicine and Medical Engineering, Taipei Medical University, Taipei 110, Taiwan.
  • International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 110, Taiwan.
  • Nano Targeting & Therapy Biopharma Inc., Taipei 110, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

ORCID-Profile: Tsung-I Hsu, Yi-Ping Chen, Chung-Yuan Mou, Si-Han Wu

Förderung

  • Ministry of Science and Technology, Taiwan
  • TMU Industry-Academic Cooperation Program
  • ScinoPharm Taiwan, Ltd

Zitieren

APA

Hsu, T. I., Chen, Y. P., Zhang, R. L., Chen, Z. A., Wu, C. H., Chang, W. C., Mou, C. Y., Chan, H. W., & Wu, S. H. (2024). Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c04289

Vancouver

Hsu TI, Chen YP, Zhang RL, Chen ZA, Wu CH, Chang WC, et al. Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c04289

BibTeX
@article{Hsu2024,
  author = {Hsu, Tsung-I and Chen, Yi-Ping and Zhang, Rong-Lin and Chen, Zih-An and Wu, Cheng-Hsun and Chang, Wen-Chang and Mou, Chung-Yuan and Chan, Hardy Wai-Hong and Wu, Si-Han},
  title = {Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  doi = {10.1021/acsami.4c04289}
}
Kostenlos starten →